Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO)-conjugated vectors: An in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development

Molecular Psychiatry

Volumn 20, Issue 8, 2015, Pages 1017-1026

  Girardi, G ^a,b   Fraser, J ^c   Lennen, R ^d   Vontell, R ^b   Jansen, M ^d   Hutchison, G ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY; PLACENTAL GROWTH FACTOR; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; VASCULOTROPIN; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE A; NANOPARTICLE; PHOSPHOLIPID ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ANXIETY; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN LEVEL; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOARCHITECTURE; DEVELOPMENTAL DISORDER; FETUS; FETUS DEVELOPMENT; IN VIVO STUDY; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; LIVER FUNCTION; MENTAL DISEASE; MOTHER; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NERVE FIBER; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSTETRICS; OXIDATIVE STRESS; PLACENTA INSUFFICIENCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; EMBRYOLOGY; FEMALE; LIVER; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACENTA; PLACENTAL INSUFFICIENCY; PREGNANCY; PROCEDURES;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ANXIETY; BRAIN; COMPLEMENT C3; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FEMALE; FERRIC COMPOUNDS; LIPOPOLYSACCHARIDES; LIVER; MAGNETIC RESONANCE IMAGING; MICE, INBRED C57BL; MOTOR ACTIVITY; NANOPARTICLES; PLACENTA; PLACENTAL INSUFFICIENCY; PREGNANCY; PREGNANCY OUTCOME;

EID: 84937818102     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.110     Document Type: Article

References (39)

1. Elovitz M. Anti-inflammatory interventions in pregnancy: now and the future. Semin Fetal Neonatal Med 2006; 11: 327-332.
2. Denny KJ, Woodruff TM, Taylor SM, Callaway LK. Complement in pregnancy: a delicate balance. Am J Reprod Immunol 2013; 69: 3-11.
3. Girardi G, Prohászka Z, Bulla R, Tedesco F, Scherjon S. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol 2011; 48: 1621-1630.
4. Gonzalez JM, Franzke CW, Yang F, Romero R, Girardi G. Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am J Pathol 2011; 179: 838-849.
5. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-1654.
6. De Carolis S, Botta A, Santucci S, Salvi S, Moresi S, Di Pasquo E et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 2012; 21: 776-778.
7. Lee J, Romero R, Xu Y, Kim JS, Topping V, Yoo W et al. A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, antihuman leukocyte antigen antibodies, and C4d. PLoS One 2011; 6: e16806.
8. Pedroni SM, Gonzalez JM, Wade J, Jansen MA, Serio A, Marshall I et al. Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim Biophys Acta 2014; 1842: 107-115.
9. Abisror N, Mekinian A, Lachassinne E, Nicaise-Roland P, De Pontual L, Chollet-Martin S et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum 2013; 43: 348-351.
10. Motta M, Boffa MC, Tincani A, Avcin T, De Carolis S, Lachassinne E. Follow-up of babies born to mothers with antiphospholipid syndrome: preliminary data from the European neonatal registry. Lupus 2012; 21: 761-763.
11. Motta M, Zambelloni C, Rodriguez-Perez C, Angeli A, Lojacono A, Tincani A et al. Cerebral ultrasound abnormalities in infants born to mothers with autoimmune disease. Arch Dis Child Fetal Neonatal Ed 2011; 96: F355-F358.
12. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 2011; 1: 35-40.
13. Monestier M, Kandiah DA, Kouts S, Novick KE, Ong GL, Radic MZ et al. Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin: species specificity and charge-dependent binding. J Immunol 1996; 156: 2631-2641.
14. Mastellos D, Prechl J, László G, Papp K, Oláh E, Argyropoulos E et al. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol Immunol 2004; 40: 1213-1221.
15. Shamsipour F, Zarnani AH, Ghods R, Chamankhah M, Forouzesh F, Vafaei S et al. Conjugation of monoclonal antibodies and rat IgG1 to super paramagnetic iron oxide nanoparticles for detection of her2/neu antigen on breast cancer cell lines. Avicenna J Med Biotech 2009; 1: 27-31.
16. Zhu XM, Wang YX, Leung KC, Lee SF, Zhao F, Wang DW et al. Enhanced cellular uptake of aminosilane coated superparamagnetic iron oxide nanoparticles in mammalian cell lines. Int J Nanomedicine 2012; 7: 953-964.
17. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM et al. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 2003; 14: 670-679.
18. Schmuel LC, Alberston C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 1997; 751: 37-47.
19. Kim HJ, Magrané J. Isolation and culture of neurons and astrocytes from the mouse brain cortex. Methods Mol Biol 2011; 793: 63-75.
20. Cohen D, Buurma A, Goemaere NN, Girardi G, le Cessie S, Scherjon S et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011; 225: 502-511.
21. Yamashita K, Yoshioka Y, Higashisaka K, Mimura K, Morishita Y, Nozaki M et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Biotechnol 2011; 6: 321-328.
22. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when Where Why Lancet 2005; 365: 891-900.
23. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009; 8: 110-124.
24. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
25. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65: 1869-1873.
26. Diamond D, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves Maybe it's the antibodies. Nat Rev Immunol 2009; 9: 449-456.
27. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110: 2423-2431.
28. Heininger U, Desgrandchamps D, Schaad UB. Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age. Vaccine 2006; 24: 3258-3260.
29. Fox E, Amaral D, Van de Waters J. Maternal and fetal anti-brain antibodies in development and diseases. Dev Neurobiol 2012; 72: 1327-1334.
30. Grether JK, Nelson KB, Dambrosia JM, Phillips TM. Interferons and cerebral palsy. J Pediatr 1999; 134: 324-332.
31. Vasthare US, Barone FC, Sarau HM, Rosenwasser RH, DiMartino M, Young WF et al. Complement depletion improves neurological function in cerebral ischemia. Brain Res Bull 1998; 45: 413-419.
32. Figueroa E, Gordon LE, Feldhoff PW, Lassiter HA. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett 2005; 380: 48-53.
33. Cowell RM, Plane JM, Silverstein FS. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J Neurosci 2003; 23: 9459-9468.
34. Lew SM, Gross CE, Bednar MM, Russell SJ, Fuller SP, Ellenberger C et al. Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke. Brain Res Bull 1999; 48: 325-331.
35. Lassiter HA, Feldhoff RC, Dabhia N, Parker JC Jr, Feldhoff PW. Complement inhibition does not reduce post-hypoxic-ischemic cerebral injury in 21-day-old rats. Neurosci Lett 2001; 302: 37-40.
36. Järlestedt K, Rousset CI, Ståhlberg A, Sourkova H, Atkins AL, Thornton C et al. Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxicischemic brain injury. FASEB J 2013; 27: 3797-3804.
37. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. soldiers returning from Iraq. N Engl J Med 2008; 358: 453-463.
38. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100: 613-619.
39. Sargsyan SA, Serkova NJ, Renner B, Hasebroock KM, Larsen B, Stoldt C et al. Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int 2012; 81: 152-159.